Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.

CPT Pharmacometrics Syst Pharmacol · 2025 · PMC12521056 · PMID 40613748

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

Also, the random effects were not centered on 0, with highly significant deviations ( p < 0.0001) for the apparent central volume of distribution (V2/F), the apparent peripheral volume of distribution (V3/F), and T lag ; and the largest deviation corresponding to a 43% higher V2/F.

also in 132,142 other papers

a negative trendno p-value reported

In addition, the GOF plots showed a negative trend in residuals with respect to the time since first dose and latest dose as well as population prediction.

also in 4,201 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.